FDA clears Andrew Technologies liposuction device

24 April 2013 (Last Updated April 24th, 2013 18:30)

The US Food and Drug Administration (FDA) has granted 510(k) clearance to Andrew Technologies' liposuction device.

The US Food and Drug Administration (FDA) has granted 510(k) clearance to Andrew Technologies' liposuction device.

Based on the company's proprietary Tissue Liquefaction technology, the Autologous Fat Transfer device reinjects the adipose tissue harvested during a HydraSolve liposuction procedure into the same patient for rejuvenation or augmentation.

Combining natural saline solution with low levels of pressure and temperature, Hydrasolve liquefies only targeted fat tissue while preserving blood vessels, nerves and connective tissue integrity.

"Based on the company's proprietary Tissue Liquefaction technology, the Autologous Fat Transfer device reinjects the adipose tissue harvested during a HydraSolve liposuction procedure into the same patient for rejuvenation or augmentation."

The specially designed HydraSolve cannula is also manufactured with aperture edges that have a rounded radius of curvature that do not cut tissue, according to the company.

Andrew Technologies chief scientific officer Dr Mark Andrew said; "We are extremely pleased to take a leading role in providing technology for autologous fat grafting that we believe can improve the process for the surgeon and the outcome for the patient."

Meridian Plastic Surgeons plastic surgeon Dr Bruce Van Natta said; "I have found that HydraSolve rapidly removes fat and produces a nearly bloodless fat layer of uniform particles that can be easily injected into breasts and other target tissues."

Andrew Technologies CEO Tom Albright said; "We are thrilled to achieve our second FDA clearance in less than 6 months, as a startup medical device company that is quite an accomplishment."